High-Sialic IgE Fc Receptor Dimer for Lower-Side-Effect Allergy Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, such as asthma and atopic dermatitis, face challenges with insufficient efficacy and severe side effects, particularly from high-dose administration of anti-IgE antibodies like omalizumab.
Innovation Solution
A polypeptide dimer comprising two monomers of the extracellular domain of the alpha subunit of the IgE Fc receptor with a high sialic acid content, designed to bind strongly to IgE and minimize side effects by avoiding Fc gamma receptor interaction, is developed for subcutaneous delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose administration of omalizumab is used to maintain therapeutic effects, then therapeutic efficacy is improved, but side effects such as angioedema, anaphylactic reaction, and serious adverse reactions increase
Solution Approach 1:
The patent modifies the molecular structure of the therapeutic agent by changing the sialic acid content parameter. The polypeptide dimer is engineered to have a specific sialic acid content (0.1-10 μmol/mg protein) to optimize binding affinity to IgE while reducing harmful interactions with Fc gamma receptors, thereby maintaining therapeutic efficacy at lower doses and reducing side effects
Solution Approach 2:
The patent creates a composite molecular structure by combining the extracellular domain of the alpha subunit of IgE Fc receptor with an Fc region, forming a chimeric polypeptide dimer. This composite structure integrates the binding capability of the FcεRIα-ECD with the pharmacokinetic properties of the Fc region, achieving both high affinity IgE binding and reduced side effects
2Reliability
If conventional anti-IgE antibodies are used to treat allergic diseases, then IgE binding is achieved, but binding affinity is insufficient and high doses are required
Solution Approach 1:
The patent optimizes the binding affinity parameter by engineering the polypeptide dimer with specific sialic acid content (0.1-10 μmol/mg protein). This parameter modification enables the polypeptide to achieve high-affinity binding to IgE, reducing the dose concentration required for therapeutic effect
Solution Approach 2:
The patent divides the functional domains into separate components: the extracellular domain of the alpha subunit (FcεRIα-ECD) provides IgE binding functionality, while the Fc region provides pharmacokinetic properties. This segmentation allows each component to be optimized independently for its specific function
3Reliability
If polypeptide dimer with high sialic acid content is designed to bind strongly to IgE, then binding affinity is improved, but risk of Fc gamma receptor interaction and side effects increases
Solution Approach 1:
The patent applies local quality modification by controlling the sialic acid content specifically at the binding interface region. The polypeptide dimer is engineered to have elevated sialic acid content (0.1-10 μmol/mg protein) at the IgE binding site to enhance affinity, while the overall molecular structure is designed to avoid Fc gamma receptor interaction sites
Solution Approach 2:
The patent uses sialic acid as an intermediary molecule that mediates the binding between the polypeptide dimer and IgE. The sialic acid residues on the polypeptide dimer form binding interfaces with IgE, enabling high-affinity interaction while the Fc region acts as a spacer that prevents direct interaction with Fc gamma receptors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide dimer with high sialic acid content exhibits enhanced binding affinity to IgE, maintains high concentration in the blood, and reduces severe side effects, providing effective prevention or treatment for allergic diseases.
Implementation Method 1
the polypeptide dimer with high sialic acid content exhibits enhanced binding affinity to IgE
Implementation Method 2
comprising extracellular domain of alpha subunit of ige fc receiver, wherein the molar ratio of sialic acid/polypeptide dimer is at least 8
Data Source
AI summary
A modified IgE Fc receptor having a high content of sialic acid and a pharmaceutical composition contains the modified IgE Fc receptor are disclosed. The polypeptide dimer having a high content of sialic acid not only has excellent safety and persistence in a body as compared with conventionally used anti-IgE antibodies, but also shows strong binding to IgE. Thus, the polypeptide has the advantage of an extended administration cycle. The polypeptide dimer is also an IgE single target substance, and unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied, does not bind to an Fc gamma receptor. The polypeptide dimer can be usefully used for the prevention or treatment of allergic diseases.